# A Phase 2 Single-Arm Open-Label Pilot Trial Evaluating Zanidatamab (ZW25) in Patients With Early Stage HER2/Neu Positive (HER2+) Breast Cancer (BC)

> **NCT05035836** · PHASE2 · RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 20 (estimated)

## Conditions studied

- Breast Cancer
- HER2-positive

## Interventions

- **DRUG:** Zanidatamab
- **DRUG:** Letrozole
- **DRUG:** Tamoxifen

## Key facts

- **NCT ID:** NCT05035836
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-11-16
- **Primary completion:** 2028-12-29
- **Final completion:** 2028-12-29
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2025-12-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05035836

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05035836, "A Phase 2 Single-Arm Open-Label Pilot Trial Evaluating Zanidatamab (ZW25) in Patients With Early Stage HER2/Neu Positive (HER2+) Breast Cancer (BC)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05035836. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*